The Prognostic Value of Excision Repair Cross-Complementation Group 1 (ERCC1) in Patients with Small Cell Lung Cancer (SCLC) Receiving Platinum-Based Chemotherapy: Evidence from Meta-Analysis

• Yanlong Yang ,

  Contributed equally to this work with: Yanlong Yang, Xiuping Luo, Nuo Yang

  Affiliation Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

  ⨯
• Xiuping Luo ,

  Contributed equally to this work with: Yanlong Yang, Xiuping Luo, Nuo Yang

  Affiliation Department of Chemotherapy, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

  ⨯
• Nuo Yang ,

  Contributed equally to this work with: Yanlong Yang, Xiuping Luo, Nuo Yang

  Affiliation Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

  ⨯
• Ronghao Feng,

  Affiliation Department of Chemotherapy, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

  ⨯
• Lei Xian

  * E-mail: xianlei59@163.com

  Affiliation Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

  ⨯